跳至主要内容
临床试验/CTRI/2015/05/005792
CTRI/2015/05/005792尚未招募未知

Retrospective analysis of efficacy and toxicity profile of first line Tyrosine kinase inhibitors in the treatment of metastatic Renal cell carcinoma- Experience from a Tertiary Referral centre.

ot Applicable0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
ot Applicable
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Inclusion criteria :
  • 1. Age more than 18 years.
  • 2. Performance status ECOG 0 to 2.
  • 3. Metastatic RCC with measurable disease.
  • 4. All histopathological diagnosis of renal cell carcinoma.
  • 5. Treated with TKIs (Sorafenib, Sunitinib & Pazopanib) in 1st line setting.

排除标准

  • 1. Non metastatic RCC.
  • 2. Non measurable disease.
  • 3. Patients progressed on first line treatment.
  • 4. Uncontrolled co morbidities.

研究者

发起方
ot Applicable

相似试验